Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis
Status:
Recruiting
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2 study of bomedemstat (IMG-7289), an inhibitor of
lysine-specific demethylase 1 (LSD1), in combination with JAK inhibition (JAKi) in patients
with myelofibrosis.